The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
A Giannoudis, L Wang, AL Jorgensen… - Blood, The Journal …, 2013 - ashpublications.org
Although the prognosis of chronic myeloid leukemia (CML) patients treated with imatinib is
good, many fail to develop an optimal response or lose one. This heterogeneity could be …
good, many fail to develop an optimal response or lose one. This heterogeneity could be …
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
A Giannoudis, L Wang, AL Jorgensen… - …, 2013 - pubmed.ncbi.nlm.nih.gov
Although the prognosis of chronic myeloid leukemia (CML) patients treated with imatinib is
good, many fail to develop an optimal response or lose one. This heterogeneity could be …
good, many fail to develop an optimal response or lose one. This heterogeneity could be …
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
A Giannoudis, L Wang, AL Jorgensen, G Xinarianos… - Blood, 2013 - eprints.gla.ac.uk
Although the prognosis of chronic myeloid leukemia (CML) patients treated with imatinib is
good, many fail to develop an optimal response or lose one. This heterogeneity could be …
good, many fail to develop an optimal response or lose one. This heterogeneity could be …
[PDF][PDF] The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
A Giannoudis, L Wang, AL Jorgensen, G Xinarianos… - BLOOD, 2013 - Citeseer
Although the prognosis of chronic myeloid leukemia (CML) patients treated with imatinib is
good, many fail to develop an optimal response or lose one. This heterogeneity could be …
good, many fail to develop an optimal response or lose one. This heterogeneity could be …
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.
A Giannoudis, L Wang, AL Jorgensen, G Xinarianos… - Blood, 2012 - europepmc.org
Although the prognosis of chronic myeloid leukemia (CML) patients treated with imatinib is
good, many fail to develop an optimal response or lose one. This heterogeneity could be …
good, many fail to develop an optimal response or lose one. This heterogeneity could be …
[PDF][PDF] The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
A Giannoudis, L Wang, AL Jorgensen, G Xinarianos… - BLOOD, 2013 - researchgate.net
Although the prognosis of chronic myeloid leukemia (CML) patients treated with imatinib is
good, many fail to develop an optimal response or lose one. This heterogeneity could be …
good, many fail to develop an optimal response or lose one. This heterogeneity could be …
[HTML][HTML] The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
A Giannoudis, L Wang, AL Jorgensen, G Xinarianos… - Blood, 2013 - Elsevier
Although the prognosis of chronic myeloid leukemia (CML) patients treated with imatinib is
good, many fail to develop an optimal response or lose one. This heterogeneity could be …
good, many fail to develop an optimal response or lose one. This heterogeneity could be …
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
A Giannoudis, L Wang, AL Jorgensen, G Xinarianos… - Blood, 2013 - research.edgehill.ac.uk
Although the prognosis of chronic myeloid leukemia (CML) patients treated with imatinib is
good, many fail to develop an optimal response or lose one. This heterogeneity could be …
good, many fail to develop an optimal response or lose one. This heterogeneity could be …